Literature DB >> 8595877

A novel, mitogen-activated nuclear kinase is related to a Drosophila developmental regulator.

G V Denis1, M R Green.   

Abstract

Although the ultimate targets of many signal transduction pathways are nuclear transcription factors, the vast majority of known protein kinases are cytosolic. Here, we report on a novel human kinase that is present exclusively in the nucleus. Kinase activity is increased upon cellular proliferation and is markedly elevated in patients with acute and chronic lymphocytic leukemias. We have identified a human gene that encodes this nuclear kinase and find that it is closely related to Drosophila female sterile homeotic (fsh), a developmental regulator with no known biochemical activity. Collectively, these results suggest that this nuclear kinase is a component of a signal transduction pathway that plays a role in Drosophila development and human growth control.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8595877     DOI: 10.1101/gad.10.3.261

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  65 in total

1.  A regulatory shortcut between the Snf1 protein kinase and RNA polymerase II holoenzyme.

Authors:  S Kuchin; I Treich; M Carlson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies.

Authors:  D R Schwam; R L Luciano; S S Mahajan; L Wong; A C Wilson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.

Authors:  A Dey; J Ellenberg; A Farina; A E Coleman; T Maruyama; S Sciortino; J Lippincott-Schwartz; K Ozato
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis.

Authors:  Anup Dey; Farideh Chitsaz; Asim Abbasi; Tom Misteli; Keiko Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-02       Impact factor: 11.205

Review 5.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

6.  Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the Drosophila female sterile homeotic (fsh) gene.

Authors:  G M Platt; G R Simpson; S Mittnacht; T F Schulz
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes.

Authors:  Jianxin You; Viswanathan Srinivasan; Gerald V Denis; William J Harrington; Mary E Ballestas; Kenneth M Kaye; Peter M Howley
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines.

Authors:  Gerald V Denis; Mark E McComb; Douglas V Faller; Anupama Sinha; Paul B Romesser; Catherine E Costello
Journal:  J Proteome Res       Date:  2006-03       Impact factor: 4.466

9.  BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

Authors:  Miguel F Segura; Bárbara Fontanals-Cirera; Avital Gaziel-Sovran; María V Guijarro; Doug Hanniford; Guangtao Zhang; Pilar González-Gomez; Marta Morante; Luz Jubierre; Weijia Zhang; Farbod Darvishian; Michael Ohlmeyer; Iman Osman; Ming-Ming Zhou; Eva Hernando
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

10.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.